Format

Send to

Choose Destination
J Cancer Res Ther. 2019;15(4):743-750. doi: 10.4103/jcrt.JCRT_903_18.

Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.

Author information

1
Department of Oncology, The Second Clinical Medical College, Jingzhou Central Hospital, Yangtze University, Jingzhou, Hubei 434020, China.
2
Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117, China.

Abstract

The development of inhibitors of immune checkpoints has revolutionized the treatment for a subset of patients with advanced nonsmall cell lung cancer (NSCLC), resulting in promising clinical outcomes and durable responses. Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been approved as a first-line treatment for patients with advanced NSCLC with PD-L1 expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. Pembrolizumab in combination with standard chemotherapy has shown better clinical outcomes than chemotherapy as a first-line therapy in patients with advanced NSCLC without targetable mutations, regardless of PD-L1 expression. In this review, we summarized the current indications of pembrolizumab for NSCLC, briefly described immune-relevant pneumonitis and discussed potential biomarkers to predict clinical efficacy.

KEYWORDS:

Immune checkpoint inhibitor; nonsmall cell lung cancer; pembrolizumab; programmed cell death-1

PMID:
31436226
DOI:
10.4103/jcrt.JCRT_903_18
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center